NEUROCRINE BIOSCIENCES INC (NBIX)

Every figure this model derived for NBIX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 34,000,000 PaymentsToAcquirePropertyPlantAndEquipment 2025-12-31
cash 389,800,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 1,637,500,000 AssetsCurrent 2026-06-30
current liabilities 874,500,000 LiabilitiesCurrent 2026-06-30
equity 3,693,600,000 StockholdersEquity 2026-06-30
interest expense 2,900,000 InterestExpenseNonoperating 2026-06-30
ocf 898,100,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 3,373,900,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 234,500,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up NBIX on one particular measure came for.

RatioValue
cash operating margin31.36
current ratio1.87
current ratio reported1.87
deferred revenue growth-92.83
dilution pct-1.16
ebit cagr39.37
ebit yoy60.57
fcf margin25.61
growth cv0.34
interest cover274.07
operating margin23.56
owner earnings margin18.66
revenue growth34.42
revenue growth per share36.0
roic19.01
rule of 4057.98
sbc pct revenue6.95

What to be careful about

What this model itself distrusts about NBIX's figures. Written by the derivation as it ran, not added afterwards.